Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) NonCurrent Deferred Liabilities : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Cyclacel Pharmaceuticals NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Cyclacel Pharmaceuticals's non-current deferred liabilities for the quarter that ended in Dec. 2023 was $0.00 Mil.

Cyclacel Pharmaceuticals NonCurrent Deferred Liabilities Historical Data

The historical data trend for Cyclacel Pharmaceuticals's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals NonCurrent Deferred Liabilities Chart

Cyclacel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

NonCurrent Deferred Liabilities

Get a 7-Day Free Trial

Cyclacel Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Cyclacel Pharmaceuticals NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCCP.PFD) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

CYCC:USA UXI:Germany

Address

200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922

Website

https://www.cyclacel.com

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.